Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky cut its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 23.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 121,900 shares of the company’s stock after selling 36,400 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Roivant Sciences were worth $1,407,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ROIV. Clearbridge Investments LLC grew its holdings in shares of Roivant Sciences by 51.3% in the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock valued at $19,666,000 after purchasing an additional 630,712 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Roivant Sciences by 40.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after buying an additional 185,226 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in shares of Roivant Sciences during the 3rd quarter valued at approximately $2,267,000. TOMS Capital Investment Management LP acquired a new position in Roivant Sciences in the third quarter valued at approximately $46,333,000. Finally, SG Americas Securities LLC acquired a new position in Roivant Sciences in the second quarter valued at approximately $472,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ROIV. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America increased their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the sale, the director now owns 22,179,358 shares in the company, valued at $262,160,011.56. This represents a 3.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the transaction, the chief operating officer now owns 617,470 shares of the company’s stock, valued at $7,193,525.50. The trade was a 13.94 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,677,309 shares of company stock valued at $43,283,184. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $12.15 on Wednesday. The stock has a market capitalization of $8.84 billion, a price-to-earnings ratio of 2.15 and a beta of 1.25. The business has a 50-day moving average of $11.90 and a 200 day moving average of $11.46. Roivant Sciences Ltd. has a 12 month low of $9.69 and a 12 month high of $13.06.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.